![img-0.jpeg](img-0.jpeg)

|  | Rotarod test | MES test |  | Peroylenetetrazol |  | Bicuculline |  | Picrotoxin |  | Strychnine |  |
| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |
|  | $\mathrm{TD}_{50}$ ( $95 \% \mathrm{Cl}$ ) | $\mathrm{ED}_{50}$ ( $95 \% \mathrm{Cl}$ ) | $\mathrm{PD}_{50}$ ( $95 \% \mathrm{Cl}$ ) | $\mathrm{ED}_{50}$ ( $95 \% \mathrm{Cl}$ ) |  | $\mathrm{ED}_{50}$ ( $95 \% \mathrm{Cl}$ ) |  | $\mathrm{ED}_{50}$ ( $95 \% \mathrm{Cl}$ ) |  | $\mathrm{ED}_{50}$ ( $95 \% \mathrm{Cl}$ ) |  |
| AED | $\mathrm{mg} / \mathrm{kg}$ | $\mathrm{mg} / \mathrm{kg}$ | Pl | $\mathrm{mg} / \mathrm{kg}$ | Pl |  | $\mathrm{mg} / \mathrm{kg}$ | Pl | $\mathrm{mg} / \mathrm{kg}$ | Pl | $\mathrm{mg} / \mathrm{kg}$ | Pl |
| Rufinamide | $>300$ | 15.5 (12.5-18.1) | $>32.5$ | 54.0 (38.1-74.9) | $>9.3$ | 50.5 (23.5-87.8) | $>9.7$ | 76.3 (64.0-90.7) | 125 | NA | $>6.6$ | 125 |
| Phenytoin | 65.5 (52.5-72.1) | 9.3 (8.1-10.4) | 6.9 | 300 no protection | $<0.2$ | 100 no protection | $<0.7$ | 100 no protection | $<0.7$ | $55-100^{b}$ | $<0.7$ |
| Phenobarbital | 69.0 (62.8-72.9) | 21.8 (15.0-25.5) | 3.2 | 13.2 (5.9-15.9) | 5.2 | 37.7 (26.5-47.4) | 1.8 | 27.5 (20.9-34.8) | 2.5 | 95.3 (91.3-99.5) | 0.7 |
| Valproate | 425.8 (369-450) | 272 (247-338) | 1.6 | 148.6 (123-177) | 2.9 | 359.9 (294-439) | 1.7 | 387.2 (341-444) | 1.1 | 292.9 (261-323) | 1.5 |
| Ethosuximide | 440.8 (383-485) | 1,000 no protection | $<0.4$ | 130.3 (111-151) | 3.4 | 459.0 (350-633) | 1.0 | 243 (228-255) | 1.8 | $250-1,000^{c}$ | $<0.4$ |


|  |  |
| :-- | :-- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

## Pentylenetetrazol-induced seizure test

Rank order for relative potencies of the intraperitoneal administration of AEDs in the pentylenetetrazol-induced clonic seizure test in mice was phenobarbital $>$ rufinamide $>>$ valproate $=$ ethosuximide $>>$ phenytoin (Table 1). Phenytoin was ineffective up to a dose of $300 \mathrm{mg} / \mathrm{kg}$. In slight contrast, the rank order for relative anticonvulsant potency in this test with oral administration in mice was phenobarbital $>$ rufinamide $>$ ethosuximide $>>$ valproate $>>>$ phenytoin (Table 2).

Oral rufinamide ( $\geq 1,000 \mathrm{mg} / \mathrm{kg}$ ) and phenytoin ( 800 $\mathrm{mg} / \mathrm{kg}$ ) did not inhibit pentylenetetrazol-induced seizures in rats (Table 3). Phenobarbital achieved the best anticonvulsive potency of the remaining three AEDs.

## Bicuculline-, picrotoxin-, and strychnine-induced seizure tests in mice

Intraperitoneal rufinamide was effective at nontoxic doses in the bicuculline and picrotoxin clonic seizure tests $\left(\mathrm{ED}_{50} \sim 50-75 \mathrm{mg} / \mathrm{kg}\right)$ and showed partial protection from strychnine-induced tonic seizures ( $37.5 \%$ protection; Table 1). Overall, the general order of potency in these chemically induced seizure tests was phenobarbital $\geq$ rufinamide $>>$ valproate $=$ ethosuximide $>$ phenytoin (Table 1). In the strychnine-induced tonic seizure test, phenytoin had the lowest $\mathrm{ED}_{50}$ value, suggesting the greatest potency. However, it is important to note that $50 \%$ protection was the maximum achieved with this AED. Phenytoin failed to provide protection against bicuculline- and picrotoxin-induced clonic seizures in mice.

## Evaluation of behavioral toxicity in mice

The median toxic dose of intraperitoneal rufinamide $\left(\mathrm{TD}_{50}\right)$ in the rotorod test of behavioral impairment was $500-1,000 \mathrm{mg} / \mathrm{kg}$. The $\mathrm{TD}_{50}$ for rufinamide was higher than that for comparator AEDs (Table 1), indicating a lower toxicity. Higher doses of rufinamide were not assessed due the low $\mathrm{ED}_{50}$ values and high protective index $(>40)$.

Neurological side effects of very high-dose intraperitoneal rufinamide $(1,000 \mathrm{mg} / \mathrm{kg}, \mathrm{n}=2 ; \mathrm{ED}_{50} 15-100$ $\mathrm{mg} / \mathrm{kg}$ ) included decreased motor activity, ataxia, muscle relaxation, decreased respiration, and death (one animal died; the other appeared normal). Higher doses of the comparator drugs induced increased side effects $\left(2 \times \mathrm{TD}_{50}\right)$ and resulted in death (all animals) in $3-24 \mathrm{~h}\left(4 \times \mathrm{TD}_{50}\right)$. The safety ratio for rufinamide in mice $\left(\mathrm{TD}_{5} / \mathrm{ED}_{97}>19.2\right.$ [intraperitoneal] and $>23.8$ [oral]) was consistently greater than for phenytoin, phenobarbital, and valproate (Table 4).

The median dose of intraperitoneal rufinamide required to produce loss of righting reflex in mice $\left(\mathrm{HD}_{50}\right)$ was $>500$ and $<1,000 \mathrm{mg} / \mathrm{kg}$ (Table 5). Rufinamide had a numerically greater $\mathrm{HD}_{50}$ value than phenytoin or phenobarbital $\left(\mathrm{HD}_{50}\right.$ values of 178 and $135 \mathrm{mg} / \mathrm{kg}$, respectively). Rufinamide, ethosuximide, and valproate had comparable